Mosquito-borne Diseases Drug Development Pipeline Review, 2018 Report - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Mosquito-borne Diseases Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

“Mosquito-borne Diseases Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under development and key players involved in therapeutic development for West Nile virus infections, Japanese encephalitis, yellow fever and malaria. It also features dormant and discontinued products.

West Nile infection, Japanese encephalitis and yellow fever are all caused by flaviviruses, whereas malaria is caused by a parasite (Plasmodium). Symptoms of West Nile infection include a fever, headache, body aches, skin rash, and swollen lymph glands. There are 18 products in development for this indication.

Japanese encephalitis affects the membranes around the brain. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. There are 17 products in development for this indication.

Yellow fever is an acute systemic illness (hemorrhagic fever). Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There are 15 products in development for this indication.

Malaria is a life-threatening blood disease. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. There are 206 products in development for this indication.

Molecular targets acted on by products in development for mosquito-borne diseases include interferon receptors, toll-like receptors and pathogen proteins such as Plasmodium falciparum merozoite surface proteins. Companies operating in this pipeline space include Sanaria, Medigen and Ology Bioservices.


Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

4SC AG AbbVie Inc Abivax SA Adimmune Corp Agilvax Inc Akshaya Bio Inc Cadila Healthcare Ltd Carna Biosciences Inc Celgene Corp CEL-SCI Corp GlaxoSmithKline Plc Hager Biosciences LLC Hawaii Biotech Inc Hemispherx Biopharma Inc iBio Inc Ichor Medical Systems Inc ID Pharma Co Ltd Immunovaccine Inc Indian Immunologicals Ltd IPCA Laboratories Ltd Merck KGaA Microbiotix Inc Mitsubishi Tanabe Pharma Corp Mymetics Corp Nobelpharma Co Ltd Novartis AG Panacea Biotec Ltd PaxVax Inc Pfizer Inc Rodos BioTarget GmbH Sanaria Inc Sanofi SBI Pharmaceuticals Co Ltd Takeda Pharmaceutical Co Ltd VLP Biotech Inc

For more information about this report visit https://www.researchandmarkets.com/research/g8wzcq/mosquitoborne?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005973/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:58 PM/DISC: 06/11/2018 01:58 PM


Update hourly